Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren in previously treated nonsense mutation dystrophinopathy
NCT01557400Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- May 2012
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of ataluren in Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), sponsored by PTC Therapeutics, Inc.. Started May 2012; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT01557400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01557400.